FORM 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

i Orani O	_		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	ANNUAL	STA	λΤΕ

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL

OMB APPROVAL									
OMB Number:	OMB Number: 3235-0362								
Estimated average	Estimated average burden								
hours per response: 1.0									

Form 3 Holdings Reported.

Form 4 Transactions Reported.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OWNERSHIP

			or decirit de(ii) or the investment demparty records			
1. Name and Address of Reporting Person* Young Caroline			2. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [CPIX]		tionship of Reporting Pers all applicable) Director	10% Owner
(Last) (First) (Middle) 2525 WEST END AVENUE SUITE 950 (Street) NASHVILLE TN 37203 (City) (State) (Zip)		(Middle)	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2020		Officer (give title below)	Other (specify below)
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	ridual or Joint/Group Filing Form filed by One Repoi Form filed by More than Person	ting Person

1. Title of Security (Instr. 3)	2. Transaction	2A. Deemed	3.	4. Securities A) or Disposed	5. Amount of	6. Ownership	7. Nature of
	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)	Of (D) (Instr. 3,	4 and 5)		Securities Beneficially Owned at end of	Ownership Form: Direct (D) or	Indirect Beneficial Ownership
		(5,	Amount	(A) or (D)	Price	Issuer's Fiscal Year (Instr. 3 and 4)	Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock	10/01/2020		L4	15(1)(2)	A	\$3.29	10,083	D	
Common Stock	10/02/2020		L4	15	A	\$3.33	10,098	D	
Common Stock	10/05/2020		L4	15	A	\$3.35	10,113	D	
Common Stock	10/06/2020		L4	15	A	\$3.35	10,128	D	
Common Stock	10/07/2020		L4	15	A	\$3.24	10,143	D	
Common Stock	10/08/2020		L4	15	A	\$3.24	10,158	D	
Common Stock	10/09/2020		L4	15	A	\$3.25	10,173	D	
Common Stock	10/12/2020		L4	15	A	\$3.23	10,188	D	
Common Stock	10/13/2020		L4	15	A	\$3.21	10,203	D	
Common Stock	10/14/2020		L4	15	A	\$3.14	10,218	D	
Common Stock	10/15/2020		L4	15	A	\$3.07	10,233	D	
Common Stock	10/16/2020		L4	15	A	\$3.07	10,248	D	
Common Stock	10/19/2020		L4	15	A	\$3.03	10,263	D	
Common Stock	10/20/2020		L4	15	A	\$3.04	10,278	D	
Common Stock	10/21/2020		L4	15	A	\$3.04	10,293	D	
Common Stock	10/22/2020		L4	15	A	\$3.08	10,308	D	
Common Stock	10/23/2020		L4	15	A	\$3.04	10,323	D	
Common Stock	10/26/2020		L4	15	A	\$3.02	10,338	D	
Common Stock	10/27/2020		L4	15	A	\$3.06	10,353	D	
Common Stock	10/28/2020		L4	15	A	\$2.97	10,368	D	
Common Stock	10/29/2020		L4	15	A	\$3.02	10,383	D	
Common Stock	10/30/2020		L4	15	A	\$2.99	10,398	D	
Common Stock	11/02/2020		L4	15	A	\$2.97	10,413	D	
Common Stock	11/03/2020		L4	15	A	\$2.99	10,428	D	
Common Stock	11/04/2020		L4	15	A	\$3.01	10,443	D	
Common Stock	11/05/2020		L4	15	A	\$2.98	10,458	D	
Common Stock	11/06/2020		L4	15	A	\$2.99	10,473	D	
Common Stock	11/09/2020		L4	15	A	\$3.06	10,488	D	
Common Stock	11/10/2020		L4	15	A	\$3.09	10,503	D	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
Date	te onth/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr.	Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of	6. Ownership Form: Direct	7. Nature of Indirect Beneficial
		(мопширау/теаг)	6)	Amount	(A) or (D)	Price	Issuer's Fiscal Year (Instr. 3 and 4)	(D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock 11	1/11/2020		L4	15	A	\$3.12	10,518	D	
		ive Securities				***	,	=	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

(e.g., puts, cans, warrants, options, convertible securities								curities)							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	of		Expiration Date (Month/Day/Year)			d 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Amount of Securities Underlying Oerivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. The purchase reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020.
- 2. Filing 5 of 6

Remarks:

Caroline Young by /s/ Michael 02/05/2021 Bonner as attorney-in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.